Loading…
Pharmacologic cardioversion with intravenous amiodarone is likely safe in neurocritically Ill patients
Highlights • We evaluated the safety of cardioversion of new onset neurogenic atrial fibrillation in the brain injured patient using intravenous amiodarone. • We found that pharmacologic cardioversion with intravenous amiodarone without anticoagulation is likely safe in the brain injured patient. •...
Saved in:
| Published in: | Journal of clinical neuroscience 2017-05, Vol.39, p.59-61 |
|---|---|
| Main Authors: | , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | cdi_FETCH-LOGICAL-c362t-d40b019748b135fed67941346a09a482b09f95aaf82f812bc72f61c5870efde83 |
| container_end_page | 61 |
| container_issue | |
| container_start_page | 59 |
| container_title | Journal of clinical neuroscience |
| container_volume | 39 |
| creator | Su, Michael Seki, David Moheet, Asma M |
| description | Highlights • We evaluated the safety of cardioversion of new onset neurogenic atrial fibrillation in the brain injured patient using intravenous amiodarone. • We found that pharmacologic cardioversion with intravenous amiodarone without anticoagulation is likely safe in the brain injured patient. • Intravenous amiodarone may be considered for the treatment of atrial fibrillation in the brain injured patient. |
| doi_str_mv | 10.1016/j.jocn.2017.01.014 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1869964898</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0967586816310840</els_id><sourcerecordid>1869964898</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-d40b019748b135fed67941346a09a482b09f95aaf82f812bc72f61c5870efde83</originalsourceid><addsrcrecordid>eNp9kV-L1TAQxYMo7nX1C_ggffSl10mapimIIIt_FhYU1OeQphM33TS5Ju1d7rc35a4--CAMzCScc2B-Q8hLCnsKVLyZ9lM0Yc-AdnugpfgjsqNtw2om2uYx2UEvurqVQl6QZzlPANDzBp6SCyZZGQXsiP16q9OsTfTxpzOV0Wl08Ygpuxiqe7fcVi4sSR8xxDVXenZx1CkGrFyuvLtDf6qytuUZqoBriia5xRnty_-199VBLw7Dkp-TJ1b7jC8e-iX58fHD96vP9c2XT9dX729q0wi21COHAWjfcTnQprU4iq7ntOFCQ6-5ZAP0tm-1tpJZSdlgOmYFNa3sAO2Isrkkr8-5hxR_rZgXNbts0HsdsCygqBR9L7jsNyk7S02KOSe06pDcrNNJUVAbXzWpja_a-CqgpXgxvXrIX4cZx7-WP0CL4O1ZgGXLo8OksikEDI4uoVnUGN3_89_9YzfehQ3oHZ4wT3FNofBTVGWmQH3bLrwdmIqGguTQ_AarC6Kt</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1869964898</pqid></control><display><type>article</type><title>Pharmacologic cardioversion with intravenous amiodarone is likely safe in neurocritically Ill patients</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Su, Michael ; Seki, David ; Moheet, Asma M</creator><creatorcontrib>Su, Michael ; Seki, David ; Moheet, Asma M</creatorcontrib><description>Highlights • We evaluated the safety of cardioversion of new onset neurogenic atrial fibrillation in the brain injured patient using intravenous amiodarone. • We found that pharmacologic cardioversion with intravenous amiodarone without anticoagulation is likely safe in the brain injured patient. • Intravenous amiodarone may be considered for the treatment of atrial fibrillation in the brain injured patient.</description><identifier>ISSN: 0967-5868</identifier><identifier>EISSN: 1532-2653</identifier><identifier>DOI: 10.1016/j.jocn.2017.01.014</identifier><identifier>PMID: 28209460</identifier><language>eng</language><publisher>Scotland: Elsevier Ltd</publisher><subject>Administration, Intravenous ; Aged ; Aged, 80 and over ; Amiodarone ; Amiodarone - administration & dosage ; Amiodarone - adverse effects ; Anti-Arrhythmia Agents - administration & dosage ; Anti-Arrhythmia Agents - adverse effects ; Arrhythmias, cardiac ; Atrial fibrillation ; Atrial Fibrillation - diagnosis ; Atrial Fibrillation - drug therapy ; Atrial Fibrillation - physiopathology ; Brain injuries, complications ; Cardioversion ; Critical Illness - therapy ; Electric Countershock - methods ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Nervous System Diseases - diagnosis ; Nervous System Diseases - drug therapy ; Nervous System Diseases - physiopathology ; Neurology ; Prospective Studies ; Retrospective Studies ; Risk Factors ; Sympathetic nervous system, pathology ; Thromboembolism - chemically induced ; Thromboembolism - diagnosis ; Thromboembolism - physiopathology</subject><ispartof>Journal of clinical neuroscience, 2017-05, Vol.39, p.59-61</ispartof><rights>Elsevier Ltd</rights><rights>2017 Elsevier Ltd</rights><rights>Copyright © 2017 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c362t-d40b019748b135fed67941346a09a482b09f95aaf82f812bc72f61c5870efde83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28209460$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Su, Michael</creatorcontrib><creatorcontrib>Seki, David</creatorcontrib><creatorcontrib>Moheet, Asma M</creatorcontrib><title>Pharmacologic cardioversion with intravenous amiodarone is likely safe in neurocritically Ill patients</title><title>Journal of clinical neuroscience</title><addtitle>J Clin Neurosci</addtitle><description>Highlights • We evaluated the safety of cardioversion of new onset neurogenic atrial fibrillation in the brain injured patient using intravenous amiodarone. • We found that pharmacologic cardioversion with intravenous amiodarone without anticoagulation is likely safe in the brain injured patient. • Intravenous amiodarone may be considered for the treatment of atrial fibrillation in the brain injured patient.</description><subject>Administration, Intravenous</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Amiodarone</subject><subject>Amiodarone - administration & dosage</subject><subject>Amiodarone - adverse effects</subject><subject>Anti-Arrhythmia Agents - administration & dosage</subject><subject>Anti-Arrhythmia Agents - adverse effects</subject><subject>Arrhythmias, cardiac</subject><subject>Atrial fibrillation</subject><subject>Atrial Fibrillation - diagnosis</subject><subject>Atrial Fibrillation - drug therapy</subject><subject>Atrial Fibrillation - physiopathology</subject><subject>Brain injuries, complications</subject><subject>Cardioversion</subject><subject>Critical Illness - therapy</subject><subject>Electric Countershock - methods</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Nervous System Diseases - diagnosis</subject><subject>Nervous System Diseases - drug therapy</subject><subject>Nervous System Diseases - physiopathology</subject><subject>Neurology</subject><subject>Prospective Studies</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Sympathetic nervous system, pathology</subject><subject>Thromboembolism - chemically induced</subject><subject>Thromboembolism - diagnosis</subject><subject>Thromboembolism - physiopathology</subject><issn>0967-5868</issn><issn>1532-2653</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp9kV-L1TAQxYMo7nX1C_ggffSl10mapimIIIt_FhYU1OeQphM33TS5Ju1d7rc35a4--CAMzCScc2B-Q8hLCnsKVLyZ9lM0Yc-AdnugpfgjsqNtw2om2uYx2UEvurqVQl6QZzlPANDzBp6SCyZZGQXsiP16q9OsTfTxpzOV0Wl08Ygpuxiqe7fcVi4sSR8xxDVXenZx1CkGrFyuvLtDf6qytuUZqoBriia5xRnty_-199VBLw7Dkp-TJ1b7jC8e-iX58fHD96vP9c2XT9dX729q0wi21COHAWjfcTnQprU4iq7ntOFCQ6-5ZAP0tm-1tpJZSdlgOmYFNa3sAO2Isrkkr8-5hxR_rZgXNbts0HsdsCygqBR9L7jsNyk7S02KOSe06pDcrNNJUVAbXzWpja_a-CqgpXgxvXrIX4cZx7-WP0CL4O1ZgGXLo8OksikEDI4uoVnUGN3_89_9YzfehQ3oHZ4wT3FNofBTVGWmQH3bLrwdmIqGguTQ_AarC6Kt</recordid><startdate>20170501</startdate><enddate>20170501</enddate><creator>Su, Michael</creator><creator>Seki, David</creator><creator>Moheet, Asma M</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170501</creationdate><title>Pharmacologic cardioversion with intravenous amiodarone is likely safe in neurocritically Ill patients</title><author>Su, Michael ; Seki, David ; Moheet, Asma M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-d40b019748b135fed67941346a09a482b09f95aaf82f812bc72f61c5870efde83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Administration, Intravenous</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Amiodarone</topic><topic>Amiodarone - administration & dosage</topic><topic>Amiodarone - adverse effects</topic><topic>Anti-Arrhythmia Agents - administration & dosage</topic><topic>Anti-Arrhythmia Agents - adverse effects</topic><topic>Arrhythmias, cardiac</topic><topic>Atrial fibrillation</topic><topic>Atrial Fibrillation - diagnosis</topic><topic>Atrial Fibrillation - drug therapy</topic><topic>Atrial Fibrillation - physiopathology</topic><topic>Brain injuries, complications</topic><topic>Cardioversion</topic><topic>Critical Illness - therapy</topic><topic>Electric Countershock - methods</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Nervous System Diseases - diagnosis</topic><topic>Nervous System Diseases - drug therapy</topic><topic>Nervous System Diseases - physiopathology</topic><topic>Neurology</topic><topic>Prospective Studies</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Sympathetic nervous system, pathology</topic><topic>Thromboembolism - chemically induced</topic><topic>Thromboembolism - diagnosis</topic><topic>Thromboembolism - physiopathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Su, Michael</creatorcontrib><creatorcontrib>Seki, David</creatorcontrib><creatorcontrib>Moheet, Asma M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical neuroscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Su, Michael</au><au>Seki, David</au><au>Moheet, Asma M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacologic cardioversion with intravenous amiodarone is likely safe in neurocritically Ill patients</atitle><jtitle>Journal of clinical neuroscience</jtitle><addtitle>J Clin Neurosci</addtitle><date>2017-05-01</date><risdate>2017</risdate><volume>39</volume><spage>59</spage><epage>61</epage><pages>59-61</pages><issn>0967-5868</issn><eissn>1532-2653</eissn><abstract>Highlights • We evaluated the safety of cardioversion of new onset neurogenic atrial fibrillation in the brain injured patient using intravenous amiodarone. • We found that pharmacologic cardioversion with intravenous amiodarone without anticoagulation is likely safe in the brain injured patient. • Intravenous amiodarone may be considered for the treatment of atrial fibrillation in the brain injured patient.</abstract><cop>Scotland</cop><pub>Elsevier Ltd</pub><pmid>28209460</pmid><doi>10.1016/j.jocn.2017.01.014</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0967-5868 |
| ispartof | Journal of clinical neuroscience, 2017-05, Vol.39, p.59-61 |
| issn | 0967-5868 1532-2653 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1869964898 |
| source | ScienceDirect Freedom Collection 2022-2024 |
| subjects | Administration, Intravenous Aged Aged, 80 and over Amiodarone Amiodarone - administration & dosage Amiodarone - adverse effects Anti-Arrhythmia Agents - administration & dosage Anti-Arrhythmia Agents - adverse effects Arrhythmias, cardiac Atrial fibrillation Atrial Fibrillation - diagnosis Atrial Fibrillation - drug therapy Atrial Fibrillation - physiopathology Brain injuries, complications Cardioversion Critical Illness - therapy Electric Countershock - methods Female Follow-Up Studies Humans Male Middle Aged Nervous System Diseases - diagnosis Nervous System Diseases - drug therapy Nervous System Diseases - physiopathology Neurology Prospective Studies Retrospective Studies Risk Factors Sympathetic nervous system, pathology Thromboembolism - chemically induced Thromboembolism - diagnosis Thromboembolism - physiopathology |
| title | Pharmacologic cardioversion with intravenous amiodarone is likely safe in neurocritically Ill patients |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T02%3A53%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacologic%20cardioversion%20with%20intravenous%20amiodarone%20is%20likely%20safe%20in%20neurocritically%20Ill%20patients&rft.jtitle=Journal%20of%20clinical%20neuroscience&rft.au=Su,%20Michael&rft.date=2017-05-01&rft.volume=39&rft.spage=59&rft.epage=61&rft.pages=59-61&rft.issn=0967-5868&rft.eissn=1532-2653&rft_id=info:doi/10.1016/j.jocn.2017.01.014&rft_dat=%3Cproquest_cross%3E1869964898%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c362t-d40b019748b135fed67941346a09a482b09f95aaf82f812bc72f61c5870efde83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1869964898&rft_id=info:pmid/28209460&rfr_iscdi=true |